Navigation Links
Oncothyreon announces issuance of patent for PX-867
Date:3/20/2008

BELLEVUE, WA, March 20 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) today announced that the U.S. Patent and Trademark office has issued a patent for PX-867, a small molecule compound currently in preclinical development. The newly issued patent, U.S. Patent # 7,335,679, includes claims covering both composition of matter of PX-867 and pharmaceutical preparations containing PX-867.

PX-867 is an inhibitor of the phosphatidylinositol-3-kinase (PI-3-kinase)/PTEN/Akt pathway, the same pathway targeted by Oncothyreon's small molecule compound PX-866, which is expected to enter clinical development in 2008. Signaling through this pathway plays a critical role in the survival of cancer cells, and also contributes to a number of other disease states, including cardiovascular disease and autoimmune disease. The preclinical development for PX-867 has focused on cardiovascular disease. In particular, the compound has demonstrated activity as a coating on intravascular stents in preclinical models of atherosclerotic disease.

"We intend to seek a partner to develop PX-867 in non-oncology indications, particularly in cardiovascular applications, while focusing our internal development efforts on PX-866 in oncology, our core area of expertise," said Robert L. Kirkman, M.D. President and CEO of Oncothyreon. "We expect to file an Investigational New Drug Application for PX-866 in the coming quarter and to initiate a Phase 1 trial soon thereafter."

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon to present at upcoming investment conferences
2. Oncothyreon reports full year and fourth quarter 2007 financial results
3. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
4. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
5. Oncothyreon launches new corporate website
6. Oncothyreon to present at BIO CEO & Investor Conference
7. Oncothyreon highlights corporate and clinical objectives for 2008
8. Biomira announces plan to change name to Oncothyreon
9. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
10. Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up
11. BioMS Medical Announces 2007 Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... As part of its philanthropic partnership with ... Foundation funded a $3.25 million project to relocate and ... most up-to-date features and technology. , The new pharmacy ... staff members will begin moving from the current location ... days. , The current pharmacy has been using ...
(Date:5/20/2015)... Calif. , May 20, 2015 ... today presented preliminary data demonstrating the ability of ... pulmonary fibrosis (IPF) from other interstitial lung diseases ... suggest the classifier,s potential to help thousands of ... resolve ambiguity in IPF diagnosis – a frequent ...
(Date:5/20/2015)... The global genotyping market is expected to grow ... of 2015 to 2020 to reach $17.0billion in 2020. ... and development process and to provide personalized therapy, factors ... investments by key manufacturers to offer advanced and innovative ... Browse 113 market data tables & 37 figures spread ...
(Date:5/20/2015)... DIEGO , May 20, 2015  Cypher ... announced a collaboration with Celgene Corporation to apply ... genomic biomarkers that associate with patient response to ... is intended to help accelerate patient access to ... efficiencies in clinical research and development and potentially ...
Breaking Biology Technology:Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2
... WILL FOCUS ON COLLECTION, PROCESSING AND STORAGE OF EQUINE ... BONE MARROW AND PLACENTAL TISSUE STEM CELLS, RANCHO ... ), a leading supplier of innovative products and,services that ... its,wholly-owned subsidiary, Vantus, Inc., has signed a formal agreement ...
... Feb. 27 Ocera Therapeutics, a,biopharmaceutical company focused ... to treat a broad range of,gastrointestinal and liver ... joined the company as Chief Medical Officer. Prior ... Chief Medical Officer and Vice,President of Clinical Affairs ...
... Ltd, a specialty,biopharmaceutical company focused on controlling immune ... phase II clinical study with its,anti-allergy technology, ToleroMune. ... cat-dander allergy, and aims to complete the trial ... on the results of a previous double-blind,placebo-controlled phase ...
Cached Biology Technology:ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 2ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 3ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 4ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 5M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer 2Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology 2
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... a good thing better? A gene known as LIS1 is ... developing brain. When an LIS1 gene is missing, brains fail ... brain, are born severely mentally retarded. But new research by ... recently appeared in Nature Genetics, shows that having ...
... newly described fossil whales--a pregnant female and a male ... and provide new insights into how whales made the ... fossils, discovered in Pakistan in 2000 and 2004, are ... the online journal PLoS. "This stunning ...
... Albert Einstein College of Medicine of Yeshiva University have discovered ... causes disease. The study, published in the ... ( PNAS ), may help scientists develop new therapies or ... fungal infections occur most commonly in those with compromised immune ...
Cached Biology News:Weizmann Institute scientists show extra copies of a gene carry extra risk 2Early whales gave birth on land 2Scientists discover how deadly fungus protects itself 2
... The PowerEase 500 Power Supply ... electrophoresis. It offers extensive programming ... four custom methods for you ... preferences. The simple intuitive PowerEase ...
karyopherin alpha2 (2G7)...
TNF-R2 (L-20)...
50 assays. Provides an easy system for rapid separation of cytosol and particulate fractions that are compatiable with downstream studies....
Biology Products: